Serena Lattante

Dr. Serena Lattante

Dipartimento di Medicina Sperimentale, Universita' del Salento, Lecce, Puglia, Italy
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Neuron
Verified
Journal Article
Closed access
ANAude Nicolas
Aude Nicolas
KKKevin P. Kenna
Kevin P. Kenna
ARAlan E. Renton
Alan E. Renton
NTNicola Ticozzi
Nicola Ticozzi
FFFaraz Faghri
Faraz Faghri
NTNatalie A. Twine
Natalie A. Twine

30 March 2014 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
Serena LattanteSerena Lattante
Serena Lattante
JJJanel O Johnson
Janel O Johnson
EPErik P Pioro
Erik P Pioro
ABAshley Boehringer
Ashley Boehringer
RCRuth Chia
Ruth Chia
BTBryan J Traynor
Bryan J Traynor
The authors identify mutations in the MATR3 gene as a cause of ALS and dementia in several families. MATR3 is known to bind the ALS-associated protein TDP-43, and at least one of these mutations alters the efficiency of this binding. MATR3 is an RNA- and DNA-binding protein that interacts with TDP-43, a disease protein linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Using exome sequencing, we identified mutations in MATR3 in ALS kindreds. We also observed MATR3 pathology in ALS-affected spinal cords with and without MATR3 mutations. Our data provide more evidence supporting the role of aberrant RNA processing in motor neuron degeneration.

29 April 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MZMarcella Zollino
Marcella Zollino
DODaniela Orteschi
Daniela Orteschi
MMMarina Murdolo
Marina Murdolo
Serena LattanteSerena Lattante
Serena Lattante
DBDomenica Immacolata Battaglia
Domenica Immacolata Battaglia
Giuseppe MarangiGiuseppe Marangi
Giuseppe Marangi

1 March 2017 in Neurobiology of Aging
Verified
Journal Article
Open access
WSWilliam Sproviero
William Sproviero
ASAleksey Shatunov
Aleksey Shatunov
DSDaniel Richard Stahl
Daniel Richard Stahl
MSMaryam Shoai
Maryam Shoai
WRWouter van Rheenen
Wouter van Rheenen
AAAmmar Al-Chalabi
Ammar Al-Chalabi
We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclerosis (ALS). Two new case-control studies, a British dataset of 1474 ALS cases and 567 controls, and a Dutch dataset of 1328 ALS cases and 691 controls were analyzed. In addition, to increase power, we systematically searched PubMed for case-control studies published after 1 August 2010 that investigated the association between ATXN2 intermediate repeats and ALS. We conducted a meta-analysis of the new and existing studies for the relative risks of ATXN2 intermediate repeat alleles of between 24 and 34 CAG trinucleotide repeats and ALS. There was an overall increased risk of ALS for those carrying intermediate sized trinucleotide repeat alleles (odds ratio 3.06 [95% confidence interval 2.37-3.94]; p = 6 × 10-18), with an exponential relationship between repeat length and ALS risk for alleles of 29-32 repeats (R2 = 0.91, p = 0.0002). No relationship was seen for repeat length and age of onset or survival. In contrast to trinucleotide repeat diseases, intermediate ATXN2 trinucleotide repeat expansion in ALS does not predict age of onset but does predict disease risk.

1 October 2014 in Neurobiology of Aging
Verified
Journal Article
Closed access
IBIsabelle Le Ber
Isabelle Le Ber
ASAnne De Septenville
Anne De Septenville
RGRita Guerreiro
Rita Guerreiro
JBJosé Bras
José Bras
ACAgnès Camuzat
Agnès Camuzat
ABAlexis Brice
Alexis Brice

3 July 2012 in Neurology
Verified
Journal Article
Closed access
PDF file
Serena LattanteSerena Lattante
Serena Lattante
ACAmelia Conte
Amelia Conte
MZMarcella Zollino
Marcella Zollino
Marco LuigettiMarco Luigetti
Marco Luigetti
AGAlessandra Del Grande
Alessandra Del Grande
MSMario Sabatelli
Mario Sabatelli
Objectives: To quantify the overall contribution of mutations in the currently known amyotrophic lateral sclerosis (ALS) genes in a large cohort of sporadic patients and to make genotype–phenotype correlations. Methods: Screening for SOD1, TARDBP, FUS, ANG, ATXN2, OPTN, and C9ORF72 was carried out in 480 consecutive patients with sporadic ALS (SALS) and in 48 familial ALS (FALS) index patients admitted to a single Italian referral center. Results: Mutations were detected in 53 patients, with a cumulative frequency of 11. Seven of them were novel. The highest frequencies of positive cases were obtained in TARDBP (2.7%), C9ORF72 (2.5%), and SOD1 (2.1%). The overall group of mutated patients was indistinguishable from that without mutations as no significant differences were observed with regard to age and site of onset, frequency of clinical phenotypes, and survival. However, by separately evaluating genotype–phenotype correlation in single genes, clinical differences were observed among different genes. Duration of disease was significantly shorter in patients harboring the C9ORF72 expansion and longer in the SOD1 group. A high frequency of predominant upper motor neuron phenotype was observed among patients with TARDBP mutations. Two patients, 1 with C9ORF72 and 1 with SOD1 mutation, had concurrent ANG mutations. Mutations were detected in 43.7% of patients with FALS. Conclusions: A considerable proportion of patients with SALS harbored mutations in major ALS genes. This result has relevant implications in clinical practice, namely in genetic counseling. The detection of double mutations in 2 patients raises the hypothesis that multiple mutations model may explain genetic architecture of SALS. Neurology® 2012;79:66–72